Literature DB >> 17999900

Recent developments in the diagnosis and treatment of status epilepticus.

Megan Selvitelli1, Frank W Drislane.   

Abstract

Despite increased understanding of its potential complications, status epilepticus (SE) frequently remains difficult to diagnose and treat. Advances in continuous electroencephalogram (EEG) monitoring facilitate more rapid identification of SE, even without visible clinical signs of seizures. EEG monitoring assists in modifying SE treatment and in making a prognosis. Despite the improved recognition of SE, some patients continue to seize after treatment with intravenous benzodiazepines and other medications. There are new uses for valproic acid, levetiracetam, and topiramate, and they have evidence of efficacy in treating different forms of SE. If medical treatments do not terminate SE, other interventions, such as surgery and stimulation procedures, may promote seizure cessation. This article reviews recent studies evaluating the use of continuous EEG monitoring in the setting of SE, new uses of anticonvulsants, and nonpharmacologic interventions for SE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17999900     DOI: 10.1007/s11910-007-0081-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  56 in total

1.  Frequency and predictors of nonconvulsive seizures during continuous electroencephalographic monitoring in critically ill children.

Authors:  Nathalie Jette; Jan Claassen; Ronald G Emerson; Lawrence J Hirsch
Journal:  Arch Neurol       Date:  2006-12

2.  Prognostic value of EEG monitoring after status epilepticus: a prospective adult study.

Authors:  R Jaitly; J A Sgro; A R Towne; D Ko; R J DeLorenzo
Journal:  J Clin Neurophysiol       Date:  1997-07       Impact factor: 2.177

3.  Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring.

Authors:  P M Vespa; M R Nuwer; V Nenov; E Ronne-Engstrom; D A Hovda; M Bergsneider; D F Kelly; N A Martin; D P Becker
Journal:  J Neurosurg       Date:  1999-11       Impact factor: 5.115

4.  Electroconvulsive therapy for treatment of intractable seizures. Initial findings in two children.

Authors:  D A Griesemer; C H Kellner; M D Beale; G M Smith
Journal:  Neurology       Date:  1997-11       Impact factor: 9.910

5.  Nonconvulsive status epilepticus in children: clinical and EEG characteristics.

Authors:  Stacey K H Tay; Lawrence J Hirsch; Linda Leary; Nathalie Jette; John Wittman; Cigdem I Akman
Journal:  Epilepsia       Date:  2006-09       Impact factor: 5.864

6.  Treatment of refractory partial status epilepticus with multiple subpial transection: case report.

Authors:  C H D'Giano; M Del C García ; H Pomata; A L Rabinowicz
Journal:  Seizure       Date:  2001-07       Impact factor: 3.184

7.  Control of refractory status epilepticus precipitated by anticonvulsant withdrawal using left vagal nerve stimulation: a case report.

Authors:  Ravish V Patwardhan; John Dellabadia; Mahmoud Rashidi; Laurie Grier; Anil Nanda
Journal:  Surg Neurol       Date:  2005-08

8.  Safety of rapid intravenous loading of valproate.

Authors:  Nita A Limdi; Robert K Knowlton; Stacey S Cofield; Lawrence W Ver Hoef; Alfred L Paige; Sandeep Dutta; Edward Faught
Journal:  Epilepsia       Date:  2007-02-22       Impact factor: 5.864

9.  Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome.

Authors:  P M Vespa; K O'Phelan; M Shah; J Mirabelli; S Starkman; C Kidwell; J Saver; M R Nuwer; J G Frazee; D A McArthur; N A Martin
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

10.  Determinants of mortality in status epilepticus.

Authors:  A R Towne; J M Pellock; D Ko; R J DeLorenzo
Journal:  Epilepsia       Date:  1994 Jan-Feb       Impact factor: 5.864

View more
  1 in total

Review 1.  Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy.

Authors:  Roberta Celli; Francesco Fornai
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.